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Abstract
The characterization of the molecular mechanisms involved in development and progression of
melanoma could be helpful to identify the molecular profiles underlying aggressiveness, clinical
behavior, and response to therapy as well as to better classify the subsets of melanoma patients
with different prognosis and/or clinical outcome. Actually, some aspects regarding the main
molecular changes responsible for the onset as well as the progression of melanoma toward a more
aggressive phenotype have been described. Genes and molecules which control either cell
proliferation, apoptosis, or cell senescence have been implicated. Here we provided an overview
of the main molecular changes underlying the pathogenesis of melanoma. All evidence clearly
indicates the existence of a complex molecular machinery that provides checks and balances in
normal melanocytes. Progression from normal melanocytes to malignant metastatic cells in
melanoma patients is the result of a combination of down- or up-regulation of various effectors
acting on different molecular pathways.
Molecular complexity of melanoma 
pathogenesis
Melanocytic transformation is thought to occur by
sequential accumulation of genetic and molecular altera-
tions [1,2]. Although the pathogenetic mechanisms
underlying melanoma development are still largely
unknown, several genes and metabolic pathways have
been shown to carry molecular alterations in melanoma.
A primary event in melanocytic transformation can be
considered a cellular change that is clonally inherited and
contributes to the eventual malignancy. This change
occurs as a secondary result of some oncogenic activation
through either genetic (gene mutation, deletion, amplifi-
cation or translocation), or epigenetic (a heritable change
other than in the DNA sequence, generally transcriptional
modulation by DNA methylation and/or by chromatin
alterations such as histone modification) events. The
result of such a change would be the generation of a
melanocytic clone with a growth advantage over sur-
rounding cells. Several pathways have been found to be
involved in primary clonal alteration, including those
inducing the cell proliferation (proliferative pathways) or
overcoming the cell senescence (senescence pathway). Con-
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versely, reduced apoptosis is highly selective or required
for the development of advanced melanoma (apoptotic
pathways).
Proliferative pathways
The MAPK-ERK pathway (including the cascade of NRAS,
BRAF, MEK1/2, and ERK1/2 proteins), a major signaling
cascade involved in the control of cell growth, prolifera-
tion and migration, has been reported to play a major role
in both the development and progression of melanoma
(the increased activity of ERK1/2 proteins, which have
been found to be constitutively activated in melanomas
mostly as a consequence of mutations in upstream com-
ponents of the pathway) and seems to be implicated in
rapid melanoma cell growth, enhanced cell survival and
resistance to apoptosis [3,4].
A less common primary pathway which stimulates cell
proliferation, without MAPK activation, seems to be the
reduction of RB (retinoblastoma protein family) activity
by  CyclinD1  or  CDK4  amplification or RB mutation
(impaired RB activity through increased CDK4/cyclin D1
could substitute for the MAPK activation and initiate
clonal expansion) [4,5].
Senescence pathways
Cell senescence is an arrest of proliferation at the somatic
level, which is induced by telomere shortening, oncogenic
activation, and/or cellular stress due to intense prolifera-
tive signals [6,7]. In recent years, a common mechanism
for the induction of cell senescence has been described: a
progressive-reduction in the length of telomeres (often, in
conjunction with overactivity of specific oncogenes - such
as MYC and ATM) seems to exert DNA damage signaling
with activation of the p16CDKN2A pathway [8,9]. Neverthe-
less, cancers including melanomas cannot grow indefi-
nitely without a mechanism to extend telomeres. The
expression and activity of telomerase is indeed up-regu-
lated in melanoma progression [10]. This evidence
strongly suggests that both telomere length and
p16CDKN2A act in a common pathway leading to growth-
arrest of nevi. In particular, the p16CDKN2A protein acts as
an inhibitor of melanocytic proliferation by binding the
CDK4/6 kinases and blocking phosphorylation of the RB
protein, which leads to cell cycle arrest [11]. Dysfunction
of the proteins involved in the p16CDKN2A pathway have
been demonstrated to promote uncontrolled cell growth,
which may increase the aggressiveness of transformed
melanocytic cells [12].
Apoptotic pathways
The p14CDKN2A protein exerts a tumor suppressor effect by
inhibiting the oncogenic actions of the downstream
MDM2 protein, whose direct interaction with p53 blocks
any p53-mediated activity and targets the p53 protein for
rapid degradation [13]. Impairment of the p14CDKN2A-
MDM2-p53 cascade, whose final effectors are the Bax/Bcl-
2 proteins, has been implicated in defective apoptotic
responses to genotoxic damage and, thus, to anticancer
agents (in most cases, melanoma cells present concurrent
high expression levels of Bax/Bcl-2 proteins, which may
contribute to further increasing their aggressiveness and
refractoriness to therapy) [14,15].
The main genes and related pathways in 
melanoma
BRAF
Exposure to ultraviolet light is an important causative fac-
tor in melanoma, although the relationship between risk
and exposure is complex. Considerable roles for intermit-
tent sun exposure and sunburn history in the develop-
ment of melanoma have been identified in epidemiologic
studies [16].
The pathogenic effects of sun exposure could involve the
genotoxic, mitogenic, or immunosuppressive responses
to the damage induced in the skin by UVB and UVA
[17,18]. UVB represents only a small portion of the solar
radiation reaching the earth's surface (<5%) but it can
directly damage DNA through mutagenesis at dipyrimi-
dine sites, inducing apoptosis in keratinocytes. UVA indi-
rectly damages DNA primarily through the generation of
reactive oxygen species and formation of 8-oxo-7,8-dihy-
dro-2'-deoxyguanosine. These reactive oxygen species
subsequently damage DNA especially by the formation of
G>T transversion mutations [19].
It is controversial as to whether the UVB or the UVA com-
ponent of solar radiation is more important in melanoma
development [20,21]. One of the major reasons for this
uncertainty is that sunlight is a complex and changing mix
of different UV wavelengths, so it is very difficult to accu-
rately delineate the precise lifetime exposures of individu-
als and entire populations to UVA and UVB from
available surrogates, such as latitude at diagnosis or expo-
sure questionnaires [19]. A significant body of epidemio-
logical evidence suggests that both UVA and UVB are
involved in melanoma causation [20-24].
The clinical heterogeneity of melanoma can probably be
explained by the existence of genetically distinct types of
melanoma with different susceptibility to ultraviolet light
[5]. Cutaneous melanomas, indeed, have four distinct
subtypes:
- Superficial Spreading Melanoma (SSM), on intermittently
exposed skin (i.e., upper back);
-  Lentigo Maligna Melanoma (LMM), on chronically
exposed skin;Journal of Translational Medicine 2009, 7:86 http://www.translational-medicine.com/content/7/1/86
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- Acral Lentiginous Melanoma (ALM), on the hairless skin of
the palms and soles;
-  Nodular Melanoma (NM), with tumorigenic vertical
growth, not associated with macular component [25].
From a molecular point of view, the signaling cascades
involving the melanocortin-1-receptor  (MC1R) and RAS-
BRAF genes have been demonstrated to represent a possi-
ble target of UV-induced damage.
The MC1R gene encodes the melanocyte-stimulating hor-
mone receptor (MSHR), a member of the G-protein-cou-
pled receptor superfamily which normally signals the
downstream BRAF pathway by regulating intracellular lev-
els of cAMP [26,27]. The MC1R gene is remarkably poly-
morphic in Caucasian populations, representing one of
the major genetic factors which determines skin pigmen-
tation. Its sequence variants can result in partial (r) or
complete (R) loss of the receptor's signalling ability
[28,29]. The MC1R variants have been suggested to be
associated with red hair, fair skin, and increased risk of
both melanoma and non-melanoma skin cancers [29,30].
RAS and BRAF are two important molecules belonging to
the mitogen-activated protein kinase (MAPK) signal trans-
duction pathway, which regulates cell growth, survival,
and invasion. MAPK signaling is initiated at the cell mem-
brane, either by receptor tyrosine kinases (RTKs) binding
ligand or integrin adhesion to extracellular matrix, which
transmits activation signals via the RAS-GTPase on the cell
membrane inner surface. Active, GTP-bound RAS can
bind effector proteins such as RAF serine-threonine kinase
or phosphatidylinositol 3-Kinase (PI3K) [31,32].
In mammals, three highly conserved RAF genes have been
described: ARAF, BRAF, and CRAF (Raf-1). Although each
isoform possesses a distinct expression profile, all RAF
gene products are capable of activating the MAPK pathway
[33,34].  CRAF  and  ARAF  mutations are rare or never
found in human cancers [35-37]. This is probably related
to the fact that oncogenic activation of ARAF and CRAF
require the coexistence of two mutations [34,36]. The
BRAF gene, which can conversely be activated by single
amino acid substitutions, is much more frequently
mutated in human cancer (approximately 7% of all
types). Activating mutations of BRAF have been found in
colorectal, ovarian [3], thyroid [38], and lung cancers [39]
as well as in cholangiocarcinoma [40], but the highest rate
of  BRAF  mutations (overall, about half of cases) have
been observed in melanoma [41].
The most common mutation in BRAF gene (nearly, 90%
of cases) is a substitution of valine with glutamic acid at
position 600 (V600E) [3]. This mutation, which is present
in exon 15 within the kinase domain, activates BRAF and
induces constitutive MEK-ERK signaling in cells [3,42].
The activation of BRAF leads to the downstream expres-
sion induction of the microphthalmia-associated transcrip-
tion factor (MITF) gene, which has been demonstrated to
act as the master regulator of melanocytes. Activated BRAF
also participates in the control of cell cycle progression
(see below) [43].
Activating  BRAF  mutations have been detected in
melanoma patients only at the somatic level [44] and in
common cutaneous nevi [45]. Among primary cutaneous
melanomas, the highest prevalence of BRAF oncogenic
mutations has been reported in late stage tumors (mostly,
vertical growth phase lesions) [46,47]. Therefore, the role
of BRAF activation in pathogenesis of melanoma remains
controversial.
The presence of BRAF mutations in nevi strongly suggests
that BRAF activation is necessary but not sufficient for the
development of melanoma (also known as melanom-
agenesis). To directly test the role of activated BRAF in
melanocytic proliferation and transformation, a trans-
genic zebrafish expressing BRAF-V600E presented a dra-
matic development of patches of ectopic melanocytes
(termed as fish-nevi) [48]. Remarkably, activated BRAF in
p53-deficient zebrafish induced the formation of melano-
cytic lesions that rapidly developed into invasive melano-
mas, which resembled human melanomas in terms of
histological and biological behaviors[48]. These data pro-
vide direct evidence that the p53 and BRAF pathways
functionally interact to induce melanomagenesis. BRAF
also cooperates with CDKN2A, which maps at the CDKN
locus and encodes two proteins: the cyclin-dependent
kinase inhibitor p16CDKN2A, which is a component of the
CyclinD1-RB pathway, and the tumor suppressor
p14CDKN2A, which has been functionally linked to the
MDM2-p53 pathway (see below). Activating BRAF muta-
tions have been reported to constitutively induce up-regu-
lation of p16CDKN2A  and cell cycle arrest (this
phenomenon appears to be a protective response to an
inappropriate mitogenic signal) [4,49]. In particular,
mutant BRAF protein induces cell senescence by increas-
ing the expression levels of the p16CDKN2A protein, which,
in turn, may limit the hyperplastic growth caused by BRAF
mutations [49]. Recently, it has been demonstrated that
other factors, such as those regulated by the IGFBP7 pro-
tein, may participate in inducing the arrest of the cell cycle
and cell senescence caused by the BRAF activation [50-
52]. As for p53 deficiency, a genetic or epigenetic inactiva-
tion of p16CDKN2A gene and/or alterations of additional
cell-cycle factors may therefore contribute to the BRAF-
driven melanocytic proliferation.
The observation that early stage melanomas exhibit a
lower prevalence of BRAF mutations than that found in
late stage lesions [46,47] argues against the hypothesisJournal of Translational Medicine 2009, 7:86 http://www.translational-medicine.com/content/7/1/86
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that  BRAF  activation participates in the initiation of
melanoma but seems to strongly suggest that such an
alteration could be involved in disease progression. More-
over, similar rates of BRAF mutations have been reported
in various histological types of nevi (including congenital,
intradermal, compound, and atypical ones) [45], suggest-
ing that the activation of BRAF does not likely contribute
to possible differences in the propensity to progression to
melanoma among these nevi subsets. Taken together, all
of this evidence, strongly suggests that activating BRAF
mutations induce cell proliferation and cell survival,
which represent two biological events occurring in both
melanocytic expansion of nevi and malignant progression
from superficial to invasive disease.
Finally,  BRAF  mutations occur at high frequency in
melanomas that are strongly linked to intermittent sun
exposure (non Chronic Sun-induced Damage, non-CSD),
though sun exposure has not been shown to directly
induce the T1796→A transition underlying the V600E
change at exon 15. In fact, this transition does not affect a
dipyrimidine site and cannot be considered to be the
result of a UVB-induced replication error. Further work is
needed to better understand the interaction of UV expo-
sure and BRAF mutations. Recently, MC1R variants have
been strongly associated with BRAF mutations in non-
CSD melanoma, which has lead to the hypothesis that
BRAF activation may be somehow indirectly induced by
UV radiation [53]. In this regard, mutations in the
upstream gene NRAS which occur in about 15% of cuta-
neous melanomas (NRAS and BRAF mutations are mutu-
ally exclusive in the same tumor, suggesting functional
redundancy [5,54]), have been rarely found in melanoma
lesions arising in sun-exposed sites; they do not correlate
with the degree of sun exposure, histologic subtype, or
anatomical site [55,56].
Other distinct subgroups of melanoma have been shown
to harbor oncogenic mutations in the receptor tyrosine
kinase KIT. While BRAF mutations are the most common
oncogenic mutation in cutaneous melanoma, mucosal
melanomas and acral lentiginous melanomas often have
wild type BRAF, but may carry mutations in KIT  gene
(though, the role of such alterations in melanomagenesis
are yet to be clearly defined). In most cases, KIT mutations
are accompanied by an increase in gene copy number and
genomic amplification [57,58].
CDKN2A and CDK4
The Cyclin-Dependent Kinase Inhibitor 2A (CDKN2A,
also called Multi Tumor-Suppressor MTS1) [59] is the
major gene involved in melanoma pathogenesis and pre-
disposition. It is located on chromosome 9p21 and
encodes two proteins, p16CDKN2A (including exons 1α, 2
and 3) and p14CDKN2A (a product of an alternative splicing
that includes exons 1β and 2) [60,61], which are known
to function as tumour suppressors. The p16CDKN2A and
p14CDKN2A are simultaneously altered in multiple tumors
since most of their pathogenetic mutations occur in exon
2, which is encoded in both gene products. The inactiva-
tion of CDKN2A is mostly due to deletion, mutation or
promoter silencing (through hypermethylation).
The p16CDKN2A protein inhibits the activity of the cyclin
D1-cyclin-dependent kinase 4 (CDK4) complex, whose
function is to drive cell cycle progression by phosphor-
ylating the retinoblastoma (RB) protein. Thus, p16CDKN2A
induces cell cycle arrest at G1 phase, blocking the RB pro-
tein phosphorylation. On this regard, RB phosphoryla-
tion causes the release of the E2F transcription factor,
which binds the promoters of target genes, stimulating the
synthesis of proteins necessary for cell division. Normally
the RB protein, through the binding of E2F, prevents the
cell division. When the RB protein is absent or inactivated
by phosphorilation, E2F is available to bind DNA and
promote the cell cycle progression [62].
p14CDKN2A  stabilizes p53, interacting with the Murine
Double Minute (MDM2) protein, whose principal func-
tion is to promote the ubiquitin-mediated degradation of
the p53 tumor suppressor gene product [63-66]. The shut-
tling of p53 by MDM2 from nucleus to cytoplasm is
required for p53 to be subject to proteosome-mediated
degradation. The p53 protein has been named "guardian
of the genome", because it arrests cell division at G1 phase
to allow DNA repair or to induce apoptosis of potentially
transformed cells. In normal conditions, the expression
levels of p53 in cells are low. In response to DNA damage,
p53 accumulates and prevents cell division. Therefore,
inactivation of the TP53 gene results in an accumulation
of genetic damage in cells which promotes tumor forma-
tion [67]. In melanoma, such an inactivation is mostly
due to a functional gene silencing since the frequency of
TP53 mutations is low [68]. Different signals regulate p53
levels by controlling its binding with MDM2. Several
kinases play this role, catalyzing stress-induced phospho-
rylation of serine in the trans-activation domain of p53.
Moreover, several proteins, including E2F, stabilize p53
through the p14CDKN2A-mediated pathway. The interac-
tion of protein p300 with MDM2 promotes p53 degrada-
tion.
Data obtained from genetic and molecular studies over
the past few years have indicated that the CDKN2A locus
as the principal and rate-limiting target of UV radiation in
melanoma formation [69]. CDKN2A has been designated
as a high penetrance melanoma susceptibility gene [70];
however, the penetrance of its mutations is influenced by
UV exposure [71] and varies according to the incidence
rates of melanoma in different populations (indeed, theJournal of Translational Medicine 2009, 7:86 http://www.translational-medicine.com/content/7/1/86
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same factors that affects population incidence of
melanoma may also mediate CDKN2A mutation pene-
trance). The overall prevalence of melanoma patients who
carry a CDKN2A mutation is between 0.2% and 2%. The
penetrance of CDKN2A mutations is also greatly influ-
enced by geographic location, with reported rates of 13%
in Europe, 50% in the US, and 32% in Australia by 50
years of age; and 58% in Europe, 76% in the US, and 91%
in Australia by age 80 [72].
CDKN2A mutations are more frequent in patients with a
strong familial history of melanoma (three or more
affected family members; 35.5%) [73] compared with
patients without any history (8.2%). Moreover, the fre-
quency of CDKN2A mutations is also higher in patients
with synchronous or asynchronous multiple melanomas
(more than two diagnosed lesions, 39.1%; only two
melanomas, 10%) [72]. Although families identified with
CDKN2A  mutations display an average disease pene-
trance of 30% by 50 years of age and 67% by age 80, stud-
ies have shown that melanoma risk is greatly influenced
by the year an individual is born, levels of sun exposure,
and other modifier genes.
Correlations between the CDKN2A mutation status and
melanoma risk factors in North American melanoma-
prone families have shown that in addition to the
increased risk associated with CDKN2A  mutations, the
total number of nevi and the presence of dysplastic nevi
were associated with a higher risk of melanoma, Sun
exposure and a history of sunburn is associated with
melanoma risk in melanoma-prone families. In other
words, the melanoma risk associated with sunburn was
higher in individuals in genetically susceptible families
than in non-susceptible individuals. This finding suggests
that there are common mechanisms and/or interactions
between the CDKN2A  pathway and the UV-sensitivity
[72]. Many high-risk families exhibit atypical nevus/mole
syndrome (AMS) characterized by atypical nevi, increased
banal nevi and atypical nevus distribution on ears, scalp,
buttocks, dorsal feet and iris. In a study of CDKN2A muta-
tion carriers, a similar distribution was present on but-
tocks and feet, and in a p16CDKN2A  family with a
temperature-sensitive mutation, nevi were found to be
distributed in warmer regions of the body (head, neck and
trunk). This supports the hypothesis that p16CDKN2A muta-
tions play a role in nevus senescence.
The second melanoma susceptibility gene is the Cyclin-
Dependent Kinase 4, which is located at 12q13.6, and
which encodes a protein interacting with the p16CDKN2A
gene product. CDK4 is a rare high-penetrance melanoma
predisposition gene. Indeed, only three melanoma fami-
lies worldwide are carriers of mutations in CDK4
(Arg24Cys and Arg24His). From a functional point of
view, the Arg24Cys mutation, located in the p16CDKN2A-
binding domain of CDK4, make the p16CDKN2A protein
unable to inhibit the D1-cyclin-CDK4 complex, resulting
in a sort of oncogenic activation of CDK4.
PTEN and AKT
The PTEN gene (phosphatase and tensin homolog deleted
on chromosome 10) is located at the chromosome
10q23.3 [74] and is mutated in a large fraction of human
melanomas. The protein encoded by this gene acts as an
important tumor suppressor by regulating cellular divi-
sion, cell migration and spreading [75], and apoptosis
[76-78] thus preventing cells from growing and dividing
too rapidly or in an uncontrolled way. The PTEN protein
has at least two biochemical functions: lipid phosphatase
and protein phosphatase. The lipid phosphatase activity
of PTEN seems to have a role in tumorigenesis by induc-
ing a decrease in the function of the downstream AKT pro-
tein (also knows as protein kinase B or PKB). In particular,
the most important effectors of PTEN lipid phosphatase
activity are phosphatidylinositol-3,4,5-trisphosphate
(PIP3) and phosphatidylinositol 3,4-bisphosphate (PIP2)
that are produced during intracellular signaling by the
activation of lipid kinase phoshoinosite 3-kinase (PI3K).
PI3K activation results in an increase of PIP3 and a conse-
quent conformational change activating AKT [79]. This
latter protein is a serine/threonine kinase and belongs to
the AKT protein kinase family: AKT1, AKT2, and AKT3.
Although all AKT isoforms may be expressed in a different
cell type, they share a high degree of structural similarity
[80-83]. Under physiologic circumstances, the PI3K/
PTEN/AKT pathway is triggered by paracrine/autocrine
factors (e.g., insulin-like growth factor-I) [84].
Moreover, recent studies have also revealed a role for AKT
in the activation of NF-kB which is considered to be an
important pleiotropic transcription factor involved in the
control of cell proliferation and apotosis in melanoma.
Upon activation, NF-kB can regulate the transcription of a
wide variety of genes, including those involved in cell pro-
liferation. It has been reported that PTEN expression is
lost in melanoma cell lines with high AKT expression, sug-
gesting that the activation of AKT induced by PTEN inac-
tivation or growth factor signaling activation could
represent an important common pathway in the progres-
sion of melanoma (probably, by enhancing cell survival
through up-regulation of NF-kB and escape from apopto-
sis) [85].
AKT activation stimulates cell cycle progression, survival,
metabolism and migration through phosphorylation of
many physiological substrates [86-90]. Based on its role as
a key regulator of cell survival, AKT is emerging as a central
player in tumorigenesis. It has been proposed that a com-
mon mechanism of activation of AKT is DNA copy gainJournal of Translational Medicine 2009, 7:86 http://www.translational-medicine.com/content/7/1/86
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involving the AKT3 locus, which is found in 40-60% of
melanomas. AKT3 expression strongly correlates with
melanoma progression, and depletion of AKT3 induces
apoptosis in melanoma cells and reduces the growth of
xenografts [91-93]. Mutations in the gene encoding the
catalytic subunit of PI3K (PIK3CA) occur at high frequen-
cies in some human cancers [94], leading to constitutive
AKT activation [95] but occur at very low rates (5%) in
melanoma [96,97]. Activated AKT seems to promote cell
proliferation, possibly through the down-regulation of
the cyclin-dependent kinase inhibitor p27 as well as the
up-regulation and stabilization of cyclin D1 [98]. The acti-
vation of AKT also results in the suppression of apoptosis
induced by a number of stimuli including growth factor
withdrawal, detachment of extra-cellular matrix, UV irra-
diation, cell cycle discordance, and activation of FAS sign-
aling [88,99-101]. The mechanisms associated with the
ability of AKT to suppress apoptosis [89,99-101] include
the phosphorylation and inactivation of many pro-apop-
totic proteins, such as BAD (Bcl-2 antagonist of cell death,
a Bcl2 family member [101]), caspase-9 [102], MDM2
(that lead to increased p53 degradation [103-105]), and
the forkhead family of transcription factors [106], as well
as the activation of NF-kB [107]. It has been proposed that
UV irradiation induces apoptosis in human keratinocytes
in vitro and in vivo, and also activates survival pathways
including PIP3 kinase and its substrate AKT, in order to
limit the extent of cell death [108]. A direct correlation
between radiation resistance and levels of PI3K activity
has been indeed described. Although activating mutations
of AKT are nearly absent in melanoma (a rare mutation in
AKT1 and AKT3 genes has been recently reported in a lim-
ited number of human melanomas and melanoma cell
lines [109-111], the silencing of AKT function by targeting
PI3K inhibits cell proliferation and reduces sensitivity of
melanoma cells to UV radiation [112].
The lipid phosphatase activity of PTEN protein is able to
degrade the products of PI3K [113], suggesting that PTEN
functions may directly antagonize the activity of P13K/
AKT pathway [114,115]. As predicted by this model,
genetic inactivation of PTEN in human cancer cells leads
to constitutive activation of this AKT pathway and medi-
ates tumorigenesis. Numerous mutations and/or dele-
tions in the PTEN gene have been found in tumours
including lymphoma; thyroid, breast, and prostate carci-
nomas;, and melanoma [116-118]. PTEN somatic muta-
tions are found in 40-60% of melanoma cell lines and 10-
20% of primary melanomas [119]. The majority of such
mutations occurs in the phosphatase domain [117,118].
The contrast between the detection of a low mutation fre-
quency and a higher level of gene silencing in primary
melanomas has led to speculate that PTEN inactivation
may predominantly occur through epigenetic mecha-
nisms [120]. Several distinct methylation sites have been
found within the PTEN promoter and hypermethylation
at these sites has been demonstrated to reduce the PTEN
expression in melanoma. PTEN is involved in the inhibi-
tion of focal adhesion formation, cell spreading and
migration as well as in the inhibition of growth factor-
stimulated MAPK signaling (alterations in the BRAF-
MAPK pathway are frequently associated with PTEN-AKT
impairments [8,121]). Therefore, the combined effects of
the loss of the PTEN function may result in aberrant cell
growth, escape from apoptosis, and abnormal cell spread-
ing and migration. In melanoma, PTEN inactivation has
been mostly observed as a late event, although a dose-
dependent down-regulation of PTEN expression has been
implicated in early stages of tumorigenesis. In addition,
loss of PTEN protein and oncogenic activation of NRAS
seem to be mutually exclusive and both alterations may
cooperate with the loss of CDKN2A expression in contrib-
uting to melanoma tumorigenesis [122].
MITF
Increased interest has been focused on the activity of the
microphthalmia-associated transcriptor factor (MITF),
which is considered to be the "master regulator of
melanocytes" since it seems to be crucial for melanoblast
survival and melanocyte lineage commitment.
MITF maps on chromosomre 3p14.1-p12.3 and encodes
for a basic helix-loop-helix (hHLH)-leucine zipper pro-
tein that plays a role in the development of various cell
types, including neural crest-derived melanocytes and
optic cup-derived retinal pigment epithelial cells [123].
MITF was first identified in the mouse as a locus whose
mutation results in the absence of pigment cells causing
white coat color and deafness due to melanocyte defi-
ciency in the inner ear [124]. In humans, mutation of
MITF results in Waardenburg Syndrome IIa, a condition
characterized by white forelock and deafness [125]. A role
for MITF in pigment gene regulation has been suggested
[126-129], based on the existence of highly conserved
MITF consensus DNA binding elements in the promoters
of major pigment enzyme genes: tyrosinase, Tyrp1, Dct,
and pmel17 (all involved in the functional differentiation
of melanocytes) [130]. Transfection of MITF into cell lines
has indicated a regulatory activity of the transfected MITF
construct on the regulation of the pigmentation pathways
[131]. Increasing evidence also suggests a role for MITF in
the commitment, proliferation, and survival of melano-
cytes before and/or during neural crest cell migration
[132]. These studies suggest that MITF, in addition to its
involvement into the differentiation pathways such as
pigmentation, may play an important role in the prolifer-
ation and/or survival of developing melanocytes, contrib-
uting to melanocyte differentiation by triggering cell cycle
exit.Journal of Translational Medicine 2009, 7:86 http://www.translational-medicine.com/content/7/1/86
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The differentiation functions of MITF are displayed when
the expression levels of this protein are high. Indeed, high
MITF levels have been demonstrated to exert an anti-pro-
liferative activity in melanoma cells [133]. In this regard,
low levels of MITF protein were found in invasive
melanoma cells [134] and have been associated with poor
prognosis and clinical disease progression [131,135,136].
In a multivariate analysis, the expression of MITF in inter-
mediate-thickness cutaneous melanoma was inversely
correlated with overall survival [135]. The authors specu-
lated that MITF might be a new prognostic marker in
intermediate-thickness malignant melanoma. The reten-
tion of MITF expression in the vast majority of human pri-
mary melanomas, including non-pigmented tumors, is
consistent with this hypothesis and has also led to the
widespread use of MITF as a diagnostic tool in this malig-
nancy [135,137-139]. The MITF gene has been found to
be amplified in 15% to 20% of metastatic melanomas
[140-142]. In melanomas, MITF targets a number of genes
with antagonistic behaviors, including genes such as
CDK2 and Bcl-2, which promote cell cycle progression
and survival, as well as p21CIP1 and p16INK4A, which halt
the cell cycle [43,143-145]. Furthermore, MITF resides
downstream of two key anti-apoptotic pathways, the ERK
and the PI3-kinase pathways, suggesting that MITF could
integrate extracellular pro-survival signals [146]. Overall,
the question of whether MITF may exert a pro-survival
effect or growth inhibition in melanocytes and melanoma
is still open and not yet fully understood. One could spec-
ulate that the cellular context and microenvironment may
represent important influencing factors.
The expression and function of MITF can be regulated by
a variety of cooperating transcription factors, such as
Pax3, CREB, Sox10, Lef1, and Brn-2 [146,147] as well as
by members of the MAPK and cAMP pathways [148-150].
In melanoma cells, activated BRAF suppresses MITF pro-
tein levels through ERK-mediated phosphorylation and
degradation [133]. Furthermore, the MITF gene is ampli-
fied in 10-15% of melanomas carrying a mutated BRAF
[141], supporting the view that continued expression of
MITF is essential in melanoma cells. MITF was recently
shown to also act downstream of the canonical WNT
pathway, which includes cysteine-rich glycoproteins that
play a critical role in development and oncogenesis [151].
In particular, the WNT gene family has been demon-
strated to be involved into the development of the neural
crest during melanocyte differentiation from pluripotent
cells among several species (from zebrafish to mammali-
ans) [151-154]. Moreover, several WNT proteins have
been shown to be overexpressed in various human can-
cers; among them, the up-regulation of the WNT2 seems
to participate in inhibiting normal apoptotic machinery
in melanoma cells [155] (recently, it has been suggested
that the WNT2 protein expression levels can be also useful
in the differential diagnosis of nevus versus melanoma
[156]). A key downstream effector of this pathway is β-cat-
enin. In the absence of WNT-signals, β-catenin is targeted
for degradation through phosphorylation controlled by a
complex consisting of glycogen synthase kinase-3-beta
(GSK3β), axin, and adenomatous polyposis coli (APC)
proteins. The WNT signals lead to the inactivation of
GSK3β, thus stabilizing the intracellular levels of β-cat-
enin and subsequently increasing transcription of down-
stream target genes. Mutations in multiple components of
the WNT pathway have been identified in many human
cancers, all of the mutations induce nuclear accumulation
of β-catenin [151,157]. In human melanoma, stabilizing
mutations of β-catenin have been found in a significant
fraction of established cell lines. Almost one third of these
cell lines display aberrant nuclear accumulation of β-cat-
enin, although few mutations have been classified as
pathogeneic variants [157,158]. These observations are
consistent with the hypothesis that this pathway contrib-
utes to behavior of melanoma cells and might be inappro-
priately deregulated for the development of the disease.
In Figure 1, the main effectors of all the above-mentioned
pathways with their functional relationships are schemat-
ically reported.
Novel signaling pathways in melanoma
Notch1
Notch proteins are a family of a single-pass type I trans-
membrane receptor of 300 kDa that was first identified in
Drosophila melanogaster (at this level, a mutated protein
causes 'notches' in the fly wing [159]). In vertebrates,
there are four Notch genes encoding four different recep-
tors (Notch1-4) that differ by the number of epidermal
growth factor-like (EGF-like) repeats in the extracellular
domain, as well as by the length of the intracellular
domain [160-162]. These receptors are activated by spe-
cific transmembrane ligands which are expressed on an
adjacent cell and activate Notch signaling through a direct
cell-cell interaction (Figure 2). When a cell expressing a
Notch receptor is stimulated by the adjacent cell via a
Notch ligand on the cell surface, the extracellular subunit
is trans-endocytosed in the ligand-expressing cell. The
remaining receptor transmembrane subunit undergoes
two consecutive enzymatic cleavages. The first activating
cleavage is mediated by a metalloprotease-dependent
TNF-α Converting Enzyme (TACE) [163,164]. This step is
rapidly followed by a second cleavage in the transmem-
brane domain to generate an intracellular truncated ver-
sion of the receptor designated as NICD. Thus, the rate of
cleavage of Notch-1 is finely modulated by multiple post-
translational modifications and cellular compartmentali-
zation events. The intracellular domain of the Notch-1
receptor (NICD) can be then moved to the nucleus, where
it forms a multimeric complex with a highly conservedJournal of Translational Medicine 2009, 7:86 http://www.translational-medicine.com/content/7/1/86
Page 8 of 17
(page number not for citation purposes)
transcription factor (CBF1, a repressor in the absence of
Notch-1), and other transcriptional co-activators that
influence the intensity and duration of Notch signals (Fig-
ure 2) [165,166]. The final result is the activation of tran-
scription at the level of promoters containing CBF-1-
responsive elements, thus stimulating or repressing the
expression of various target genes [167].
The Notch signaling pathway plays a pivotal role in tissue
homeostasis and regulation of cell fate, such as self-
renewal of adult stem cells, as well as in the differentiation
of precursors along a specific cell lineage [168-170].
Increasing evidence suggests its involvement in tumori-
genesis, since deregulated Notch signaling is frequently
observed in a variety of human cancers, such as T-cell
acute lymphoblastic leukemias [171], small cell lung can-
cer [172], neuroblastoma [173,174], cervical [175,176]
and prostate carcinomas [177]. Notch can act as either an
oncogene or a tumor suppressor depending on both cellu-
lar and tissue contexts. Many studies suggest a role for
Notch1 in keratinocytes as a tumor suppressor [178]. In
such cells, Notch signaling induces cell growth arrest and
differentiation (deletion of Notch1 in murine epidermis
causes epidermal hyperplasia and skin carcinoma)
[179,180]. The anti-tumor effect of Notch1 in murine skin
Major pathways involved in melanoma Figure 1
Major pathways involved in melanoma. Pathway associated with N-RAS, BRAF, and mitogen-activated protein kinase 
(MAPK) as well as with CDKN2A and MITF are schematically represented. Arrows, activating signals; interrupted lines, inhibit-
ing signals. BAD, BCL-2 antagonist of cell death; cAMP, cyclic AMP; CDK4, Cyclin-dependent kinase 4; CDKN2A, Cyclin-
dependent kinase inhibitor of kinase 2A; ERK1/2, Extracellular-related kinase 1 or 2; IkB, inhibitor of kB protein; IKK, inhibitor-
of-kB-protein kinase; MC1R, melanocortin-1-receptor; MITF, Microphthalmia-Associated Transcription Factor; MEK1/2, 
Mitogen-activated protein kinase-extracellular related kinase 1/2; PI3K, Phosphatidylinositol 3 kinase; PIP2, Phosphatidylinositol 
bisphosphate; PIP3, Phosphatidylinositol trisphosphate; PTEN, Phosphatase and tensin homologue.Journal of Translational Medicine 2009, 7:86 http://www.translational-medicine.com/content/7/1/86
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appears to be mediated by p21Waf1/Cipinduction and
repression of WNT signaling [151,178].
Unlike keratinocyte-derived squamous cell and basal cell
carcinomas, melanomas have a significantly higher Notch
activity in comparison with normal melanocytes
[181,182]. Investigation of the expression of Notch recep-
tors and their ligands in benign and malignant cutaneous
melanocytic lesions indicate that Notch1 and Notch2, as
well as their ligands are significantly upregulated in atyp-
ical nevi and melanomas, compared to common melano-
cytic nevi [181,182]. Furthermore, a constitutively-
induced gene activation in human melanocytes strongly
suggests that Notch1 acts as a transforming oncogene in
such a cell lineage [183]. The versatile effects of Notch1
signaling on cell differentiation, proliferation, survival,
and tumorigenesis may easily explain why Notch1 plays
different roles in various types of skin cancers. Such differ-
ent activities of Notch1 in skin cancer are probably deter-
mined by its interaction with the downstream β-catenin
target. In murine skin carcinoma, β-catenin is functional
activated by Notch1 signaling and mediates tumor-sup-
pressive effects [178,184]. In melanoma, β-catenin medi-
ates oncogenic activity by also cross-talking with the WNT
pathway or by regulating N-cadherin, with different
effects on tumorigenesis depending on Notch1 activation
[185].
Recent evidence suggest that Notch1 enhances vertical
growth phase by the activation of the MAPK and AKT
pathways; inhibition of either the MAPK or PI3K-AKT
pathway reverses the tumor cell growth induced by
Notch1 signaling. Future studies aimed at identifying new
targets of Notch1 signaling will allow the assessment of
the mechanisms underlying the crosstalk between
Notch1, MAPK, and PI3K-AKT pathways. Finally, Notch
signaling can enhance the cell survival by interacting with
transcriptional factor NF-kB (NIC seems to directly interact
with NF-kB, leading to retention of NF-kB in the nucleus
of T cells) [186]. Nevertheless, it has been shown that NIC
can directly regulate IFN-γ expression through the forma-
tion of complexes between NF-kB and the IFN-γ pro-
Notch1 pathway Figure 2
Notch1 pathway. The diagram shows the mechanism of activation of the Notch receptor by a cell-cell interaction through 
specific trasmembrane ligands, followed by the translation of the intracellular domain of the Notch-1 receptor (NICD) and for-
mation of a transcription-activating multimeric complex. CSL, citrate synthase like; HAT, histone acetyltransferase; MAML, 
mastermind-like protein; SKIP, Skeletal muscle and kidney-enriched inositol phosphatase.Journal of Translational Medicine 2009, 7:86 http://www.translational-medicine.com/content/7/1/86
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moter. Although there is a lack of consensus about
crosstalk between Notch1 and NF-kB, existing data sug-
gest that two mechanisms of NF-kB activation may occur:
an early Notch-independent phase and a late Notch-
dependent activation of NF-kB [187]. Finally, RAS-medi-
ated transformation requires the presence of intact Notch
signaling; impairment of such Notch1 receptor signaling
may significantly reduce the ability of RAS to transform
cells [188,189].
In conclusion, although the precise details of the mecha-
nisms by which Notch1 signaling can contribute to
melanoma development remain to be defined, Notch1
could be clearly considered as a novel candidate gene
implicated in melanomagenesis.
iNOS
Human melanoma tumors cells are known to express the
inducible nitric oxide synthase (iNOS) enzyme, which is
responsible for cytokine induced nitric oxide (NO) pro-
duction during immune responses (Figure 3). The consti-
tutive expression of iNOS in many cancer cells along with
its strong association with poor patient survival seems to
indicate that iNOS is a molecular marker of poor progno-
sis or a putative target for therapy [190]. Nitric oxide is a
free radical that is largely synthesized by the NO synthase
(NOS) enzyme, which exists in three established iso-
forms: endothelial NOS (eNOS, NOS III) and neuronal
NOS (nNOS, NOS I), which are both constitutively
expressed and inducible NOS (iNOS, NOS II) which is
regulated at the transcriptional level by a variety of medi-
ators (such as interferon regulatory factor-1 [191,192],
NF-kB [193,194], TNF-α and INF-γ [195,196] and has
been found to be frequently expressed in melanoma [197-
200]. The iNOS gene is located at chromosome 17q11.2
and encodes a 131 kDa protein.
In normal melanocytes, the pigment molecule eumelanin
provides a redox function supporting an antioxidant
intracellular environment. In melanoma cells, a pro-oxi-
dant status has been however reported [195]. Both reac-
tive oxygen species (ROS) and reactive nitrogen oxidants
(RNS) can be identified in melanoma. It has been hypoth-
esized that NO may have a different effect on tumors on
iNOS pathway Figure 3
iNOS pathway. The functional correlation between the IRF1-activating events (mainly, through an induction regulated by NF-
kB, TNF-α, and INF-γ mediators) and expression levels of iNOS is shown. CALM, calmodulin; IkB, inhibitor of kB protein; IKK, 
inhibitor-of-kB-protein kinase; IRF1, interferon regulatory factor-1; LPS, lipopolysaccharide; NO, nitric oxide; STAT1, signal 
transducer and activator of transcription 1.Journal of Translational Medicine 2009, 7:86 http://www.translational-medicine.com/content/7/1/86
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the basis of its intracellular concentrations. High concen-
trations of NO might mediate apoptosis and inhibition of
growth in cancer cells; conversely, low concentrations of
NO may promote tumor growth and angiogenesis [196].
Although the exact function of iNOS in tumorigenesis
remains unclear, the overproduction of NO may affect the
development or progression of melanoma. It has been
shown that the transfection of iNOS gene into murine
melanoma cells induces apoptosis, suppresses tumori-
genicity, and abrogates metastasis [201,202]. More gener-
ally, NO induces apoptosis by altering the expression and
function of multiple apoptosis-related proteins (i.e.
downregulation of Bcl-2, accumulation of p53, cleavage
of PARP [203-209]). The role of iNOS in melanoma pro-
gression remains controversial. Higher levels of iNOS
have been found in subcutaneous and lymph node metas-
tases of nonprogressive melanoma as compared to metas-
tases of progressive melanoma [210], however, iNOS was
found to be expressed to a lesser extent in metastases as
compared with nevi and primary melanomas [211]. Nev-
ertheless, the expression of iNOS in lymph nodes and in-
transit metastases has been proposed as an indicator of
poor prognosis [212].
Finally, nNOS may also play a role in regulating the NO
level in cells of melanocytic lineage. The nNOS protein is
expressed in the vast majority of melanocytes and cul-
tured melanoma cells, but not in normal melanocytes.
However, approximately 49% of benign nevi, 72% of
atypical nevi, and 82% of primary malignant melanomas
have been reported to express nNOS [213]. The lack of
expression of nNOS in normal melanocytes suggests that
de novo enhanced expression of nNOS may be a marker for
an early stage of pigment cell tumor formation, since this
variation may lead to an increased level of NO that causes
tissue resistance to apoptosis [214].
Conclusion
Considering the complexity of the above described path-
ways, probably no individual genetic or molecular altera-
tion is per se crucial; rather the interaction of some or
most of such changes are involved in the generation of a
specific set of biological outcomes. For melanomagenesis,
it is possible to infer that the following alterations are
needed:
1. induction of clonal expansion, which is paramount
to the generation of a limited cell population for fur-
ther clonal selection (mutational activation of BRAF or
NRAS or amplification of CCND1 or CDK4 may pro-
vide this initiating step);
2. modifications to overcome mechanisms controlling
the melanocyte senescence, which otherwise would
halt the lesion as a benign mole. In melanoma cells
both in vitro and in vivo, a change seems to be dramat-
ically required: inactivation of the p16CDKN2A-RB path-
way (as discussed above, at least 80-90% of
uncultured melanomas do show primary inactivation
of such a pathway);
3. suppression of the apoptosis. Many of the previ-
ously described primary changes suppress the machin-
ery regulating apoptosis allowing for the progression
to the vertical growth phase stage (i.e., expression of
the AKT antiapoptotic protein was reported to induce
the conversion of the radial growth in vertical growth
in melanoma).
Despite our attempt to organize the various key molecular
alterations involved in melanomagenesis, there may be a
relatively large number of alternative primary events, each
relatively uncommon on its own, that result in a common
secondary outcome, such as upregulation of NFκB and/or
variation of the MITF expression levels. The awareness of
the existence of such an intracellular web of molecular
changes raises a critical question: can some primary alter-
ation in melanoma become suitable as target for thera-
peutic approaches?
This scenario is further complicated by the fact that the
majority of melanomas do not seem to evolve from nevi
and only about half of them are associated with dysplastic
nevi [215], strongly suggesting that melanoma may
mostly arise from normal-appearing skin without follow-
ing the classical sequential accumulation of molecular
events during tumorigenesis. Recently, it has been sug-
gested that melanomas may be derived from transformed
melanocyte stem cells, melanocyte progenitors, or de-dif-
ferentiated mature melanocytes [216,217]. Although the
origin of intradermic stem-cells has yet to be determined,
it has been postulated that the interaction with the tumor
microenvironment (including surrounding and/or
recruited fibroblasts and endothelial and inflammatory
cells) may induce such cells to transform directly into the
various cell variants (normal melanocytes, benign or
intermediate proliferating melanocytic cells, malign or
metastatic melanoma cells), without progressing through
intermediates [217]. In the very near future, the biologic
and molecular characterization of melanoma stem cells
will also clarify as to whether the well-known drug resist-
ance of melanoma resides in the existence of quiescent or
drug-resistant cancer stem cells as well as whether the
inhibition of self-renewing cancer stem cells prevents
melanoma regrowth.
What we can surely affirm is that targeting a single com-
ponent in such complex signaling pathways is unlikely to
yield a significant anti-tumor response in melanoma
patients. For this reason, further evaluation of all knownJournal of Translational Medicine 2009, 7:86 http://www.translational-medicine.com/content/7/1/86
Page 12 of 17
(page number not for citation purposes)
molecular targets along with the molecular classification
of primary melanomas could become very helpful in pre-
dicting the subsets of patients who would be expected to
be more or less likely to respond to specific therapeutic
interventions. Now is the time for successfully translating
all such research knowledge into clinical practice.
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